Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | PPARA | Q07869 | 6/20 | 0.47 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | PPARG | P37231 | 3/20 | 0.38 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.36 |
| ▸ | IKBKB | O14920 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | DRD3 | P35462 | 1/20 | 0.34 |
| ▸ | PPARD | Q03181 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4817468 | 0.81 | SMN1; SMN2 (0.53) | SMN1; SMN2PPARAPTGDR2PPARGPTPN1 | |
| SCHEMBL4820214 | 0.81 | SMN1; SMN2 (0.69) | SMN1; SMN2PPARAPPARGALDH1A1 | |
| SCHEMBL4817584 | 0.78 | SMN1; SMN2 (0.49) | SMN1; SMN2PPARAPTGDR2PPARGPTPN1 | |
| SCHEMBL4816039 | 0.78 | SMN1; SMN2 (0.55) | SMN1; SMN2PPARAPTGDR2PPARGPTPN1 | |
| SCHEMBL4816920 | 0.77 | PPARA (0.59) | SMN1; SMN2PPARAPTGDR2PPARGALDH1A1 | |
| SCHEMBL7976453 | 0.74 | SMN1; SMN2 (0.42) | SMN1; SMN2PPARAPTGDR2PPARGALDH1A1 | |
| SCHEMBL11359371 | 0.73 | SMN1; SMN2 (0.73) | SMN1; SMN2PPARAPPARGALDH1A1 | |
| SCHEMBL8935645 | 0.73 | SMN1; SMN2 (0.58) | SMN1; SMN2PPARAPTGDR2PPARG | |
| SCHEMBL8935648 | 0.73 | SMN1; SMN2 (0.58) | SMN1; SMN2PPARAPTGDR2PPARG | |
| SCHEMBL8935696 | 0.73 | PPARA (0.61) | SMN1; SMN2PPARAPTGDR2PPARGALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7417169-B2 | Amino alcohol derivatives, medicinal composition containing the same, and use of these | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2008-08-26 | — | — | US | disclosed |
| US-20070078184-A1 | Amino alcohol derivatives, medicinal composition containing the same, and use of these | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2007-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070078184-A1 | Amino alcohol derivatives, medicinal composition containing the same, and use of these | ADRB2, ADRA2A, ADRA1A | SMN1; SMN2 4525/4885PPARA 752/4885PTGDR2 156/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.